Compare Stocks

Date Range: 

 Clovis OncologyOrganiGramGossamer BioKadmonEvelo Biosciences
SymbolNASDAQ:CLVSNASDAQ:OGINASDAQ:GOSSNASDAQ:KDMNNASDAQ:EVLO
Price Information
Current Price$5.29$2.51$8.00$3.61$9.50
52 Week RangeHoldHoldBuyBuyBuy
MarketRank™
Overall Score1.41.61.71.81.6
Analysis Score3.04.23.53.53.3
Community Score2.53.02.53.22.3
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.71.71.7
Earnings & Valuation Score0.60.60.60.60.6
Analyst Ratings
Consensus RecommendationHoldHoldBuyBuyBuy
Consensus Price Target$6.67$4.41$23.00$12.75$19.80
% Upside from Price Target26.02% upside75.75% upside187.50% upside253.19% upside108.42% upside
Trade Information
Market Cap$589.75 million$820.14 million$607.28 million$620.26 million$509.19 million
Beta2.10.31.341.681.46
Average Volume11,110,49120,954,414616,8193,375,953257,168
Sales & Book Value
Annual Revenue$143.01 million$64.61 millionN/A$5.09 millionN/A
Price / Sales3.8711.59N/A121.86N/A
CashflowN/A$0.02 per shareN/AN/AN/A
Price / CashN/A101.50N/AN/AN/A
Book Value($3.17) per share$1.04 per share$5.34 per share$0.95 per share$1.88 per share
Price / Book-1.672.41N/A3.80N/A
Profitability
Net Income$-400,420,000.00$-101,290,000.00$-180,310,000.00$-61,370,000.00$-85,470,000.00
EPS($7.60)($0.08)($3.29)($0.74)($2.67)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-230.34%-207.26%N/A-768.36%N/A
Return on Equity (ROE)N/A-10.00%-64.34%-85.07%-159.17%
Return on Assets (ROA)-57.56%-7.14%-46.52%-46.46%-88.81%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.17%0.46%0.02%0.59%
Current Ratio2.33%2.66%17.36%5.76%6.24%
Quick Ratio2.14%3.39%17.36%5.76%6.24%
Ownership Information
Institutional Ownership Percentage57.83%10.84%71.96%94.78%84.57%
Insider Ownership Percentage6.60%N/A23.30%2.95%7.30%
Miscellaneous
EmployeesN/A61919512790
Shares Outstanding104.57 million298.23 million75.91 million171.82 million53.37 million
Next Earnings Date8/5/2021 (Estimated)7/20/2021 (Estimated)8/10/2021 (Estimated)8/5/2021 (Estimated)7/29/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Evelo Biosciences (NASDAQ:EVLO) Price Target Cut to $13.00 by Analysts at Morgan StanleyEvelo Biosciences (NASDAQ:EVLO) Price Target Cut to $13.00 by Analysts at Morgan Stanley
americanbankingnews.com - May 10 at 9:06 AM
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down  on Analyst DowngradeEvelo Biosciences (NASDAQ:EVLO) Shares Gap Down on Analyst Downgrade
americanbankingnews.com - May 3 at 12:16 PM
Evelo Biosciences, Inc. (NASDAQ:EVLO) Short Interest Down 17.9% in AprilEvelo Biosciences, Inc. (NASDAQ:EVLO) Short Interest Down 17.9% in April
americanbankingnews.com - May 3 at 7:18 AM
Evelo Biosciences (NASDAQ:EVLO) Posts  Earnings Results, Misses Expectations By $0.04 EPSEvelo Biosciences (NASDAQ:EVLO) Posts Earnings Results, Misses Expectations By $0.04 EPS
americanbankingnews.com - April 30 at 3:58 PM
Evelo Biosciences (NASDAQ:EVLO) Trading Up 5.2%Evelo Biosciences (NASDAQ:EVLO) Trading Up 5.2%
americanbankingnews.com - April 30 at 2:44 PM
Evelo Biosciences, Inc. (EVLO) Q1 2021 Earnings Call TranscriptEvelo Biosciences, Inc. (EVLO) Q1 2021 Earnings Call Transcript
finance.yahoo.com - April 29 at 7:02 PM
Evelo Biosciences, Inc.: Evelo Biosciences Reports First Quarter 2021 Financial Results and Business HighlightsEvelo Biosciences, Inc.: Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
finanznachrichten.de - April 29 at 9:01 AM
Evelo Biosciences Reports First Quarter 2021 Financial Results and Business HighlightsEvelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
finance.yahoo.com - April 29 at 9:00 AM
Evelo Biosciences (NASDAQ:EVLO) Trading Down 3.9%Evelo Biosciences (NASDAQ:EVLO) Trading Down 3.9%
americanbankingnews.com - April 28 at 1:58 PM
Evelo Biosciences, Inc. (NASDAQ:EVLO) Given Consensus Recommendation of "Buy" by BrokeragesEvelo Biosciences, Inc. (NASDAQ:EVLO) Given Consensus Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 27 at 4:40 AM
Zacks: Analysts Anticipate Evelo Biosciences, Inc. (NASDAQ:EVLO) Will Post Earnings of -$0.53 Per ShareZacks: Analysts Anticipate Evelo Biosciences, Inc. (NASDAQ:EVLO) Will Post Earnings of -$0.53 Per Share
americanbankingnews.com - April 26 at 10:22 PM
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $11.16Evelo Biosciences (NASDAQ:EVLO) Shares Gap Up to $11.16
americanbankingnews.com - April 23 at 11:37 AM
Evelo Biosciences (EVLO) to Release Earnings on ThursdayEvelo Biosciences (EVLO) to Release Earnings on Thursday
americanbankingnews.com - April 23 at 8:38 AM
Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
finance.yahoo.com - April 22 at 7:32 AM
Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic DermatitisEvelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis
finance.yahoo.com - April 20 at 6:12 PM
Evelo Biosciences (NASDAQ:EVLO)  Shares Down 7.2% Evelo Biosciences (NASDAQ:EVLO) Shares Down 7.2%
americanbankingnews.com - April 20 at 1:40 PM
Are Institutions Heavily Invested In Evelo Biosciences, Inc.s (NASDAQ:EVLO) Shares?Are Institutions Heavily Invested In Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Shares?
finance.yahoo.com - April 19 at 12:06 PM
Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down to $11.56Evelo Biosciences (NASDAQ:EVLO) Shares Gap Down to $11.56
americanbankingnews.com - April 19 at 12:02 PM
Evelo Biosciences (NASDAQ:EVLO) Upgraded at Jefferies Financial GroupEvelo Biosciences (NASDAQ:EVLO) Upgraded at Jefferies Financial Group
americanbankingnews.com - April 19 at 8:46 AM
Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H.Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H.
apnews.com - April 16 at 10:06 AM
Evelo Biosciences (NASDAQ:EVLO) Trading Up 6.9%Evelo Biosciences (NASDAQ:EVLO) Trading Up 6.9%
americanbankingnews.com - April 15 at 11:37 AM
Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of DirectorsEvelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors
finance.yahoo.com - April 15 at 7:52 AM
Evelo Biosciences, Inc. (EVLO) investors to reap big returns againEvelo Biosciences, Inc. (EVLO) investors to reap big returns again
marketingsentinel.com - April 13 at 9:48 AM
Market Analysts see Evelo Biosciences Inc. [EVLO] gaining to $18. Time to buy?Market Analysts see Evelo Biosciences Inc. [EVLO] gaining to $18. Time to buy?
dbtnews.com - April 13 at 9:48 AM
Thinking about buying stock in Nuance Communications, GameStop, Evelo Biosciences, Progenity, or Fortress Biotech?Thinking about buying stock in Nuance Communications, GameStop, Evelo Biosciences, Progenity, or Fortress Biotech?
marketwatch.com - April 12 at 1:28 PM
DateCompanyBrokerageAction
5/5/2021Clovis OncologyHC WainwrightLower Price Target
11/6/2020Clovis OncologySVB LeerinkLower Price Target
11/5/2020Clovis OncologyPiper SandlerLower Price Target
11/1/2020Clovis OncologyJPMorgan Chase & Co.Reiterated Rating
4/20/2020Clovis OncologyRoyal Bank of CanadaReiterated Rating
4/19/2020Clovis OncologyBank of AmericaDowngrade
11/27/2019Clovis OncologyEvercore ISIDowngrade
4/20/2021OrganiGramCIBCReiterated Rating
4/15/2021OrganiGramStifel NicolausBoost Price Target
4/14/2021OrganiGramRaymond JamesLower Price Target
4/14/2021OrganiGramCanaccord GenuityBoost Price Target
4/13/2021OrganiGramAlliance Global PartnersLower Price Target
4/8/2021OrganiGramBMO Capital MarketsUpgrade
3/11/2021OrganiGramCantor FitzgeraldReiterated Rating
8/10/2020OrganiGramJefferies Financial GroupReiterated Rating
10/16/2020Gossamer BioBarclaysLower Price Target
10/30/2019Gossamer BioBerenberg BankInitiated Coverage
11/11/2020KadmonMizuhoInitiated Coverage
9/22/2020KadmonOppenheimerReiterated Rating
1/10/2020KadmonNomura SecuritiesInitiated Coverage
2/26/2019KadmonCitigroupUpgrade
10/17/2018KadmonWBB SecuritiesUpgrade
5/10/2021Evelo BiosciencesMorgan StanleyLower Price Target
3/12/2021Evelo BiosciencesChardan CapitalBoost Price Target
1/25/2021Evelo BiosciencesJMP SecuritiesBoost Price Target
2/14/2020Evelo BiosciencesCowenReiterated Rating
(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.